explore -WSS

explore

author：explore 2025-10-01 22:39:27 - browse：82251

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： How digital therapeutics firms are pivoting after Pear's bankruptcy

focus

WSS

MoonLake credibility takes another hit with mid

Victims of gun violence feel impacts long after bullet wound

Ambulance rides for just $100? Advisers want major billing fixes

AI generated plenty of interest at JPM but not a lot of trust

Victims of gun violence feel impacts long after bullet wound

Humana cuts profit projections as Medicare Advantage costs soar

hotspot

explore

explore

Medicare proposal to cover medical devices draws a mixed reaction

Research misconduct: Proposed new rules face resistance

Anesthesiologist group: stop taking Ozempic before surgery

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

How to save PrEP access — and even expand it

White House calls on federal agencies to crack down on AI abuses

Sports medicine is finally prioritizing gender equality

How digital therapeutics firms are pivoting after Pear's bankruptcy

Hepatitis C has a cure — but many Americans still lack access to it

The new shift in health care is toward less care

Wikipedia

Diversify hospital leadership teams to protect BIPOC patient health

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

Elizabeth Holmes banned from government health programs

Victims of gun violence feel impacts long after bullet wound

AI generated plenty of interest at JPM but not a lot of trust

Prior authorization will have to move faster under new Biden rule

hotspot

focus

focus

focus